New Retaane trial kicks off

Article

The Anecortave Acetate Risk Reduction Trial (AARRT) has met its patient enrollment requirement of almost 2,600 individuals who are at high risk for developing choroidal neovascularization (CNV) or advanced age-related macular degeneration (AMD) over time, reported Jason Slakter, MD, of the Vitreous-Retina-Macular Consultants of New York, USA at the 2006 meeting of the AAO in Las Vegas.

The Anecortave Acetate Risk Reduction Trial (AARRT) has met its patient enrollment requirement of almost 2,600 individuals who are at high risk for developing choroidal neovascularization (CNV) or advanced age-related macular degeneration (AMD) over time, reported Jason Slakter, MD, of the Vitreous-Retina-Macular Consultants of New York, USA, at the 2006 meeting of the AAO in Las Vegas.

"Anecortave acetate (Retaane, Alcon Laboratories) was chosen for this trial based on preclinical data that suggest that this molecule inhibits new blood vessel formation by striking multiple targets in the angiogenic cascade," Dr Slakter said. "In addition, the drug has an excellent safety profile making it ideal for chronic, long-term suppressant therapy".

The drug is administered every six months, outside the eye. Two concurrent clinical trials on anecortave acetate are now ongoing with patients in one study receiving a 15 mg dose or sham administration and the other set of patients receiving a 30 mg dose or sham. The trials will follow patients for four years.

"Interestingly, 86% were using some type of vitamins. However, only about 50% of the patients were using the AREDS formulation," Dr Slakter noted. At baseline the average visual acuity in the study eye was 20/25 and in the non-study eye it was 20/200. Forty-six percent of patients had active disease in the non-study eye at baseline and 92% had subfoveal involvement.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.